Grindeks AS (GRD1R) - Financial and Strategic SWOT Analysis Review
Grindeks AS (GRD1R) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Grindeks focuses on the research, development, manufacture and marketing of original products, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and anti-diabetes therapeutic categories. The company provides final dosage form pharmaceutical products ranging from solid form products, solution for injections to syrups and ointments. Grindeks also provides regulatory, analytical and final dosage form contract manufacturing services to pharmaceutical companies. Through subsidiaries and representative offices, the company markets its products in the European (EU) countries, the US, Canada, Russia and other CIS countries, Japan and Vietnam. Grindeks operates subsidiary companies in Latvia, Estonia and Slovakia and is headquartered in Riga, Latvia.
Grindeks AS Key Recent Developments
Aug 27,2020: Grindeks: Results in the first half of 2020
Apr 30,2020: Grindeks Group publishes audited consolidated financial statements for 2019
Feb 28,2020: On Grindeks results in 2019
Feb 04,2020: Juris Hmelnickis appointed as the Chairman of the Board of Grindeks
Dec 19,2019: JSC Grindeks receives a certificate of Saudi Food and Drug Authority
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Grindeks focuses on the research, development, manufacture and marketing of original products, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and anti-diabetes therapeutic categories. The company provides final dosage form pharmaceutical products ranging from solid form products, solution for injections to syrups and ointments. Grindeks also provides regulatory, analytical and final dosage form contract manufacturing services to pharmaceutical companies. Through subsidiaries and representative offices, the company markets its products in the European (EU) countries, the US, Canada, Russia and other CIS countries, Japan and Vietnam. Grindeks operates subsidiary companies in Latvia, Estonia and Slovakia and is headquartered in Riga, Latvia.
Grindeks AS Key Recent Developments
Aug 27,2020: Grindeks: Results in the first half of 2020
Apr 30,2020: Grindeks Group publishes audited consolidated financial statements for 2019
Feb 28,2020: On Grindeks results in 2019
Feb 04,2020: Juris Hmelnickis appointed as the Chairman of the Board of Grindeks
Dec 19,2019: JSC Grindeks receives a certificate of Saudi Food and Drug Authority
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Grindeks AS - Key Facts
Grindeks AS - Key Employees
Grindeks AS - Key Employee Biographies
Grindeks AS - Major Products and Services
Grindeks AS - History
Grindeks AS - Company Statement
Grindeks AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Grindeks AS - Business Description
Business Segment: Active Pharmaceutical Ingredients
Overview
Performance
Business Segment: Final Dosage Forms
Overview
Performance
Geographical Segment: Estonia
Performance
Geographical Segment: Latvia
Performance
Geographical Segment: Lithuania
Performance
Geographical Segment: Other CIS Countries
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: Russia
Performance
Grindeks AS - Corporate Strategy
Grindeks AS - SWOT Analysis
SWOT Analysis - Overview
Grindeks AS - Strengths
Grindeks AS - Weaknesses
Grindeks AS - Opportunities
Grindeks AS - Threats
Grindeks AS - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grindeks AS, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 27, 2020: Grindeks: Results in the first half of 2020
Apr 30, 2020: Grindeks Group publishes audited consolidated financial statements for 2019
Feb 28, 2020: On Grindeks results in 2019
Feb 04, 2020: Juris Hmelnickis appointed as the Chairman of the Board of Grindeks
Dec 19, 2019: JSC Grindeks receives a certificate of Saudi Food and Drug Authority
Aug 29, 2019: Grindeks: results in the first six months of 2019
May 30, 2019: On “Grindeks” results in the first three months of 2019
May 14, 2019: JSC “Grindeks” Group could reach 300 million euro turnover within five years
Apr 30, 2019: Grindeks announced audited results in 2018
Mar 01, 2019: Turnover of Grindeks reaches 145.5 million euros in 2018
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Grindeks AS - Key Facts
Grindeks AS - Key Employees
Grindeks AS - Key Employee Biographies
Grindeks AS - Major Products and Services
Grindeks AS - History
Grindeks AS - Company Statement
Grindeks AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Grindeks AS - Business Description
Business Segment: Active Pharmaceutical Ingredients
Overview
Performance
Business Segment: Final Dosage Forms
Overview
Performance
Geographical Segment: Estonia
Performance
Geographical Segment: Latvia
Performance
Geographical Segment: Lithuania
Performance
Geographical Segment: Other CIS Countries
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: Russia
Performance
Grindeks AS - Corporate Strategy
Grindeks AS - SWOT Analysis
SWOT Analysis - Overview
Grindeks AS - Strengths
Grindeks AS - Weaknesses
Grindeks AS - Opportunities
Grindeks AS - Threats
Grindeks AS - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grindeks AS, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 27, 2020: Grindeks: Results in the first half of 2020
Apr 30, 2020: Grindeks Group publishes audited consolidated financial statements for 2019
Feb 28, 2020: On Grindeks results in 2019
Feb 04, 2020: Juris Hmelnickis appointed as the Chairman of the Board of Grindeks
Dec 19, 2019: JSC Grindeks receives a certificate of Saudi Food and Drug Authority
Aug 29, 2019: Grindeks: results in the first six months of 2019
May 30, 2019: On “Grindeks” results in the first three months of 2019
May 14, 2019: JSC “Grindeks” Group could reach 300 million euro turnover within five years
Apr 30, 2019: Grindeks announced audited results in 2018
Mar 01, 2019: Turnover of Grindeks reaches 145.5 million euros in 2018
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Grindeks AS, Key Facts
Grindeks AS, Key Employees
Grindeks AS, Key Employee Biographies
Grindeks AS, Major Products and Services
Grindeks AS, History
Grindeks AS, Other Locations
Grindeks AS, Subsidiaries
Grindeks AS, Key Competitors
Grindeks AS, Ratios based on current share price
Grindeks AS, Annual Ratios
Grindeks AS, Annual Ratios (Cont...1)
Grindeks AS, Annual Ratios (Cont...2)
Grindeks AS, Interim Ratios
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grindeks AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Grindeks AS, Key Facts
Grindeks AS, Key Employees
Grindeks AS, Key Employee Biographies
Grindeks AS, Major Products and Services
Grindeks AS, History
Grindeks AS, Other Locations
Grindeks AS, Subsidiaries
Grindeks AS, Key Competitors
Grindeks AS, Ratios based on current share price
Grindeks AS, Annual Ratios
Grindeks AS, Annual Ratios (Cont...1)
Grindeks AS, Annual Ratios (Cont...2)
Grindeks AS, Interim Ratios
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grindeks AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Grindeks AS, Performance Chart (2015 - 2019)
Grindeks AS, Ratio Charts
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
COMPANIES MENTIONED
Transgene SA
Sopharma AD
Olainfarm AS
Napp Pharmaceuticals Ltd
Dokumeds
Baxter Oncology GmbH
AmberCRO
Grindeks AS, Performance Chart (2015 - 2019)
Grindeks AS, Ratio Charts
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
COMPANIES MENTIONED
Transgene SA
Sopharma AD
Olainfarm AS
Napp Pharmaceuticals Ltd
Dokumeds
Baxter Oncology GmbH
AmberCRO